Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fc receptor (on antigen-presenting cells) (FcR (APC))
- Target
- FcR (APC)
- Molecular classification
- Receptor (cell surface receptor), Immunoglobulin superfamily (structural classification)
01
Overview
Fc receptors on antigen-presenting cells are transmembrane proteins of the immunoglobulin superfamily that bind the Fc region of antibodies (primarily IgG subclasses). These receptors transduce signals that regulate numerous immune functions, including phagocytosis, ADCC, antigen presentation, and cytokine secretion[4][1][6]. Their specific activities depend on the type of Fc receptor and cell type, with both activating (e.g., FcγRI, FcγRIIA, FcγRIIIA) and inhibitory (e.g., FcγRIIB) subtypes present[4][8]. Variation in Fc receptor genes alters efficiency of immune complex clearance and susceptibility to autoimmune and inflammatory diseases[4][5]. Fc receptor engagement is exploited therapeutically by monoclonal antibodies used in cancer and autoimmune diseases, linking antibody specificity with immune effector functions[2][8].
- Other names
- Fcγ receptorFcγRI (CD64)FcγRIIA/B/C (CD32)FcγRIII (CD16)FcRn
02
Mechanism of action
Enhancement of antibody-dependent cellular cytotoxicity (ADCC) via FcR engagement Modulation of phagocytosis and cytokine response Regulation of immune homeostasis and tolerance via inhibitory Fc receptors
03
Biological functions
Immune responseSignal transductionPhagocytosisAntibody-dependent cellular cytotoxicity (ADCC)Antigen presentationEndocytosis
04
Disease associations
CancerInflammationAutoimmune disease (systemic lupus erythematosus, rheumatoid arthritis)Infection
05
Safety considerations
Excessive immune activation or cytokine release (risk in antibody therapies)Autoimmunity (genetic variants can predispose to dysregulated responses)Infusion reactions (with therapeutic antibodies interacting via FcRs)
06
Interacting drugs
Rituximab
2 more in the full profile.
07
Biomarkers
FcγR gene polymorphisms (correlate with clinical response to antibody therapies)FcR subtype expression profiles on APCs
Beyond the preview
Go deeper on Fc receptor (on antigen-presenting cells) (FcR (APC)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fc receptor (on antigen-presenting cells) (FcR (APC)).